DE4232899C2 - Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer - Google Patents
Verwendung von NADH und NADPH zur Behandlung von Morbus AlzheimerInfo
- Publication number
- DE4232899C2 DE4232899C2 DE4232899A DE4232899A DE4232899C2 DE 4232899 C2 DE4232899 C2 DE 4232899C2 DE 4232899 A DE4232899 A DE 4232899A DE 4232899 A DE4232899 A DE 4232899A DE 4232899 C2 DE4232899 C2 DE 4232899C2
- Authority
- DE
- Germany
- Prior art keywords
- nadh
- disease
- nadph
- alzheimer
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 title claims abstract description 30
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 title claims abstract description 15
- 208000024827 Alzheimer disease Diseases 0.000 title abstract description 13
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 title 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims abstract description 5
- 229950006238 nadide Drugs 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 230000001976 improved effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000015654 memory Effects 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 3
- 229960001685 tacrine Drugs 0.000 description 3
- 206010036631 Presenile dementia Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007787 long-term memory Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000000718 cholinopositive effect Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4232899A DE4232899C2 (de) | 1992-09-30 | 1992-09-30 | Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer |
| IL106785A IL106785A (en) | 1992-09-30 | 1993-08-24 | Use of nadh and nadph as drugs for treating alzheimer's disease |
| AU44887/93A AU664768B2 (en) | 1992-09-30 | 1993-08-25 | Nadh and nadph as drugs for treating alzheimer's disease |
| EP93113775A EP0590321B1 (de) | 1992-09-30 | 1993-08-27 | Verwendung von NADH und NADPH zur Herstellung eines Arzneimittels zur Behandlung von Morbus Alzheimer |
| DE59307982T DE59307982D1 (de) | 1992-09-30 | 1993-08-27 | Verwendung von NADH und NADPH zur Herstellung eines Arzneimittels zur Behandlung von Morbus Alzheimer |
| DK93113775T DK0590321T3 (da) | 1992-09-30 | 1993-08-27 | Anvendelse af NADH og NADPH til fremstilling af et lægemiddel til behandling af Alzheimers sygdom |
| ZA936327A ZA936327B (en) | 1992-09-30 | 1993-08-27 | Nadh and nadph as drugs for treating alzheimer's disease |
| AT93113775T ATE162076T1 (de) | 1992-09-30 | 1993-08-27 | Verwendung von nadh und nadph zur herstellung eines arzneimittels zur behandlung von morbus alzheimer |
| ES93113775T ES2111104T3 (es) | 1992-09-30 | 1993-08-27 | Utilizacion de nadh y nadph para la fabricacion de un medicamento para el tratamiento de la enfermedad de alzheimer. |
| TW082107229A TW231268B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-09-30 | 1993-09-03 | |
| CA002105912A CA2105912C (en) | 1992-09-30 | 1993-09-10 | Nadh and nadph as drugs for treating alzheimer's disease |
| US08/122,035 US5444053A (en) | 1992-09-30 | 1993-09-15 | Method for treating symptoms of Alzheimer's with NADH and NADPH |
| NO933321A NO303482B1 (no) | 1992-09-30 | 1993-09-17 | NADH og NADPH som legemiddel til behandling av Morbus Alzheimer |
| JP26416393A JP3384847B2 (ja) | 1992-09-30 | 1993-09-28 | アルツハイマー病の治療剤 |
| MX9306049A MX9306049A (es) | 1992-09-30 | 1993-09-29 | Dinucleotido de nicotinamida-ademina y fosfato de dinucleotido de nicotinamida-adenina como farmacos para tratar la enfermedad de alzheimer. |
| CN93118853A CN1053341C (zh) | 1992-09-30 | 1993-09-30 | 还原形式的烟酰胺腺嘌呤二核苷酸或烟酰胺腺嘌呤二核苷酸磷酸或其盐的制药用途 |
| GR980400292T GR3026120T3 (en) | 1992-09-30 | 1998-02-12 | Use of NADH and NADPH for the manufacture of a medicament for the treatment of Alzheimer's disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4232899A DE4232899C2 (de) | 1992-09-30 | 1992-09-30 | Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE4232899A1 DE4232899A1 (de) | 1994-03-31 |
| DE4232899C2 true DE4232899C2 (de) | 1995-02-23 |
Family
ID=6469304
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE4232899A Expired - Lifetime DE4232899C2 (de) | 1992-09-30 | 1992-09-30 | Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer |
| DE59307982T Expired - Fee Related DE59307982D1 (de) | 1992-09-30 | 1993-08-27 | Verwendung von NADH und NADPH zur Herstellung eines Arzneimittels zur Behandlung von Morbus Alzheimer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE59307982T Expired - Fee Related DE59307982D1 (de) | 1992-09-30 | 1993-08-27 | Verwendung von NADH und NADPH zur Herstellung eines Arzneimittels zur Behandlung von Morbus Alzheimer |
Country Status (16)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5712259A (en) * | 1996-04-22 | 1998-01-27 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome |
| US5668114A (en) * | 1996-05-08 | 1997-09-16 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating hypertension |
| CA2369231C (en) * | 2000-04-28 | 2007-04-17 | Mizuno Corporation | Wrap closure and fit system of footwear |
| DE60229371D1 (de) * | 2001-05-02 | 2008-11-27 | Brni Neurosciences Inst | Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung |
| US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| DE10254995B4 (de) * | 2002-11-26 | 2005-02-10 | Juelich Enzyme Products Gmbh | Verfahren zur enzymatischen Reduktion von NAD und NADP |
| WO2004050099A1 (ja) * | 2002-12-03 | 2004-06-17 | Kyowa Hakko Kogyo Co., Ltd. | 還元型ニコチンアミドアデニンジヌクレオチドまたは還元型ニコチンアミドアデニンジヌクレオチドホスフェイトの安定化方法 |
| US20040126751A1 (en) * | 2002-12-27 | 2004-07-01 | Birkmayer Jorg G.D. | Method of prolonging the life-span of living cells using NADH, NADPH and ADP-ribose |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| TW200538181A (en) | 2004-05-18 | 2005-12-01 | Brni Neurosciences Inst | Treatment of depressive disorders |
| US9186350B2 (en) * | 2011-07-12 | 2015-11-17 | Gdb Patent Holdings, Llc | Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication |
| EP2574339A1 (de) | 2011-09-27 | 2013-04-03 | Johannes Huber | Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen |
| CN103340890B (zh) * | 2013-06-08 | 2016-04-27 | 苏州人本药业有限公司 | Nadph作为制备用于防治脑缺血性中风药物方面的应用 |
| WO2019028877A1 (zh) * | 2017-08-11 | 2019-02-14 | 邦泰生物工程(深圳)有限公司 | 一种含有nadh和nadph的组合物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814339A (en) * | 1986-02-11 | 1989-03-21 | Advanced Biologics, Inc. | Treatment for Alzheimer's disease |
| US4970200A (en) * | 1988-03-01 | 1990-11-13 | Schering Aktiengesellschaft | Agent for treatment of Parkinson's disease |
| AT397201B (de) * | 1988-06-03 | 1994-02-25 | Birkmayer Joerg Ddr | Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels |
| AT397200B (de) * | 1988-06-03 | 1994-02-25 | Birkmayer Joerg Ddr | Verwendung von selenmethionin zur herstellung eines arzneimittels |
-
1992
- 1992-09-30 DE DE4232899A patent/DE4232899C2/de not_active Expired - Lifetime
-
1993
- 1993-08-24 IL IL106785A patent/IL106785A/xx not_active IP Right Cessation
- 1993-08-25 AU AU44887/93A patent/AU664768B2/en not_active Ceased
- 1993-08-27 EP EP93113775A patent/EP0590321B1/de not_active Expired - Lifetime
- 1993-08-27 DE DE59307982T patent/DE59307982D1/de not_active Expired - Fee Related
- 1993-08-27 AT AT93113775T patent/ATE162076T1/de not_active IP Right Cessation
- 1993-08-27 DK DK93113775T patent/DK0590321T3/da active
- 1993-08-27 ZA ZA936327A patent/ZA936327B/xx unknown
- 1993-08-27 ES ES93113775T patent/ES2111104T3/es not_active Expired - Lifetime
- 1993-09-03 TW TW082107229A patent/TW231268B/zh active
- 1993-09-10 CA CA002105912A patent/CA2105912C/en not_active Expired - Fee Related
- 1993-09-15 US US08/122,035 patent/US5444053A/en not_active Expired - Fee Related
- 1993-09-17 NO NO933321A patent/NO303482B1/no unknown
- 1993-09-28 JP JP26416393A patent/JP3384847B2/ja not_active Expired - Fee Related
- 1993-09-29 MX MX9306049A patent/MX9306049A/es not_active IP Right Cessation
- 1993-09-30 CN CN93118853A patent/CN1053341C/zh not_active Expired - Fee Related
-
1998
- 1998-02-12 GR GR980400292T patent/GR3026120T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2105912C (en) | 2000-11-14 |
| US5444053A (en) | 1995-08-22 |
| ES2111104T3 (es) | 1998-03-01 |
| DE59307982D1 (de) | 1998-02-19 |
| ATE162076T1 (de) | 1998-01-15 |
| CA2105912A1 (en) | 1994-03-31 |
| DK0590321T3 (da) | 1998-09-14 |
| NO303482B1 (no) | 1998-07-20 |
| MX9306049A (es) | 1994-05-31 |
| AU4488793A (en) | 1994-04-14 |
| CN1089474A (zh) | 1994-07-20 |
| IL106785A (en) | 1997-09-30 |
| EP0590321B1 (de) | 1998-01-14 |
| CN1053341C (zh) | 2000-06-14 |
| ZA936327B (en) | 1994-03-22 |
| JPH06192106A (ja) | 1994-07-12 |
| TW231268B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1994-10-01 |
| IL106785A0 (en) | 1993-12-08 |
| GR3026120T3 (en) | 1998-05-29 |
| EP0590321A1 (de) | 1994-04-06 |
| DE4232899A1 (de) | 1994-03-31 |
| NO933321D0 (no) | 1993-09-17 |
| JP3384847B2 (ja) | 2003-03-10 |
| AU664768B2 (en) | 1995-11-30 |
| NO933321L (no) | 1994-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE4232899C2 (de) | Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer | |
| DE69028542T2 (de) | Felbamat zur Behandlung der Lennox-Gastaut syndrome | |
| DE3005208C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| EP0796103B1 (de) | Verwendung von weihrauch zur behandlung der alzheimer-krankheit | |
| DE69926804T2 (de) | Vorrichtungen zur behandlung und diagnose des restless leg syndroms | |
| DE2950463A1 (de) | Gallensaeuren enthaltende pharmazeutische zubereitung mit verlaengerter wirkungsdauer | |
| DE3101644A1 (de) | Arzneimittelpraeparate und verfahren zu ihrer herstellung | |
| DE68908117T2 (de) | N-Acetylglukosamin als zytoprotektives Mittel. | |
| DE2113215A1 (de) | Therapeutisches Kompositum | |
| DE2824165A1 (de) | Arzneimittel mit angstneurosen und angstaehnliche neurosen beseitigender wirkung und verfahren zum zubereiten des arzneimittels | |
| EP1513533A2 (de) | Pharmazeutische wirkstoffkombination sowie deren verwendung | |
| DE2758549A1 (de) | Pharmazeutische zubereitung | |
| WO2000048599A1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
| DE2527552A1 (de) | Mittel zur behandlung von krankheitszustaenden, die durch demyelierungsprozesse oder hypercholinergie bedingt werden | |
| DE19726871C1 (de) | Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe | |
| DE2131679A1 (de) | 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate | |
| DE2847836B2 (de) | Verfahren zur Gewinnung eines Terpengemisches mit antipsoriat ischer Wirksamkeit | |
| DE2117762A1 (de) | Behandlung von Alopecia und pharmazeutische Präparation für die Durchführung der Behandlung | |
| EP0493861B1 (de) | Nicotinamid-adenin-dinukleodid enthaltendes Antidepressionsmittel | |
| DE4110087A1 (de) | Benfotiaminhaltiges arzneimittel und dessen verwendung | |
| DE3400276A1 (de) | Verwendung von cdp-cholin zur behandlung von neurologischen stoerungen | |
| DE2658059A1 (de) | Mittel zur behandlung von krankhaften stoerungen des glukosestoffwechsels | |
| DE3136455C2 (de) | Verwendung von Caerulein oder dessen pharmazeutisch verträglichen Salzen bei der Bekämpfung von psychotischen Krankheitszuständen | |
| DE2831728C2 (de) | Arzneimittel zur Behandlung von Kopfschmerzen | |
| DE2755017A1 (de) | Oral verabreichbare arzneimittel mit psychostimulierender wirkung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| R071 | Expiry of right | ||
| R071 | Expiry of right |